Cetuximab, the only immunoglobulin G1 monoclonal antibody approved for the treatment of SCCHN,4 binds to the extracellular domain of the EGFR, thus preventing receptor activation and subsequent downstream signaling, leading to tumor cell apoptosis.4, 5. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.